Serial measurement of pancreatic lipase immunoreactivity concentration in dogs with immune‐mediated disease treated with prednisolone

Objectives In this pilot study, serum canine pancreatic lipase immunoreactivity was measured repeatedly in dogs with various immune‐mediated diseases that were treated with immunosuppressive doses of prednisolone. Methods Ten client‐owned dogs with newly diagnosed immune‐mediated disease that had no...

Full description

Saved in:
Bibliographic Details
Published in:Journal of small animal practice Vol. 58; no. 6; pp. 342 - 347
Main Authors: Ohta, H., Morita, T., Yokoyama, N., Osuga, T., Sasaki, N., Morishita, K., Nakamura, K., Takiguchi, M.
Format: Journal Article
Language:English
Published: Oxford, UK Blackwell Publishing Ltd 01-06-2017
Wiley Subscription Services, Inc
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives In this pilot study, serum canine pancreatic lipase immunoreactivity was measured repeatedly in dogs with various immune‐mediated diseases that were treated with immunosuppressive doses of prednisolone. Methods Ten client‐owned dogs with newly diagnosed immune‐mediated disease that had normal canine pancreatic lipase immunoreactivity concentrations (≤200 µg/l) were treated with 2 to 2.2 mg/kg prednisolone orally once daily as the initial treatment. Serum samples were obtained from each of the dogs prior to treatment and at 1‐ to 4‐week intervals during immunosuppressive treatment. The highest canine pancreatic lipase immunoreactivity concentration detected during immunosuppressive treatment was defined as the peak canine pancreatic lipase immunoreactivity. Results Peak canine pancreatic lipase immunoreactivity concentrations were classified as normal in two dogs, questionable (201 to 399 µg/l) in three dogs, and abnormal (≥400 µg/l) in five dogs. Peak canine pancreatic lipase immunoreactivity concentrations were significantly higher than baseline canine pancreatic lipase immunoreactivity concentrations but there was no evidence of clinical pancreatitis. Clinical Significance It remains unclear whether the five of 10 dogs with elevated canine pancreatic lipase immunoreactivity during prednisone treatment had subclinical pancreatitis or whether the abnormal results were a consequence of prednisolone administration.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0022-4510
1748-5827
DOI:10.1111/jsap.12652